REPLY
18.6.2024 10:01:34 CEST | Business Wire | Press release
Reply, an international group specialised in creating new business models enabled by AI and Digital Media, introduces the jury that will be tasked with evaluating and selecting the best short films for the Reply AI Film Festival, an international competition open to all creatives eager to engage in creating a short film using AI tools.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618976841/en/
Reply presents the inaugural Reply AI Film Festival, an international competition where Artificial Intelligence (AI) serves not only as a catalyst for innovation in the realm of creative storytelling but also as a tool for fostering inclusivity among younger generations in video and film production. (Photo: Reply)
Judging the works submitted in the four competition categories - Narratives, Pilots, Documentaries, and Experimental - will be: Adam Kulick, producer of successful films such as Twilight, Wuthering Heights, and The Iron Lady, as well as a Sloan Fellow at Stanford University specialising in Generative AI; Caleb & Shelby Ward, co-founders of Curious Refuge, the first online community dedicated to directors using AI in their creations; Denise Negri, a journalist from SkyTg24 and Sky Arte, known for covering prestigious film events like the Academy Awards, Cannes Film Festival, and Venice Film Festival. Also participating are Filippo Rizzante, Chief Technology Officer at Reply; Flavio Natalia, director of Ciak and ciakmagazine.it, and an author and journalist for Ansa, Rai, and Sky; as well as the Canadian duo Vallée Duhamel, comprised of Julien Vallée and Eve Duhamel, who create unique short films for international brands using captivating images and videos that blend playful approaches with experimentation in new technologies such as artificial intelligence. Monica Riccioni, Chief Executive Officer of Think Cattleya, an advertising agency that has collaborated with numerous international directors and created campaigns for renowned global brands; Paul Trillo, a director and video artist known for his conceptual and visually inventive films, integrating new tools like AI with traditional techniques; and Rob Minkoff, co-director of The Lion King (1994) and animator and director of numerous films including Stuart Little, The Haunted Mansion, and Mr. Peabody & Sherman.
The jury will select the short films submitted to the competition via the platform aiff.reply.com by July 1, 2024, interpreting the theme of this first edition of the festival: Synthetic Stories, Human Hearts, a title that celebrates the convergence of human talent and artificial intelligence. In doing so, they will follow three main criteria: creativity, which refers to the innovative scope of cinematic language; craftsmanship, meaning the overall quality and value of the short film's production; and the impact of artificial intelligence, assessing how AI tools have contributed to one or more aspects of its creation.
Adam Kulick commented, "GenAI's integration into filmmaking processes opens up a new era of creativity and justifiable concerns. I'm hopeful that the fusion of human ingenuity and these rapidly evolving technologies produces groundbreaking work and new opportunities for the filmmaking community."
"We believe AI is going to act as a creative assistant in every part of the filmmaking pipeline. It’s going to allow for new stories to be told, it’s going to democratise the filmmaking industry and support filmmakers all around the world in telling their stories." said Caleb & Shelby Ward.
"AI is an increasingly valuable ally of creativity. We are truly delighted that such high-calibre figures in the film world have joined our initiative: a space to test AI as an ally of human creativity, but also an opportunity for young talents to immerse themselves in new technologies, acquire advanced skills, and bring new narratives to life," said Filippo Rizzante.
"I have always supported the potential of AI and believe that the combination of human and technological talent is not only possible but also enriches our work. This added value is something we at Think Cattleya greatly value and I am certain I will witness it during the screening of the short films in this competition," said Monica Riccioni.
"Specifically, AI's role should always be to assist the creatives, producers and crew working in film and not to replace them. It should not be used as a crutch or a shortcut for the creatively bankrupt. This is an opportunity for independent filmmakers to think out of the box and for smaller productions to create better, bolder and stranger films." confirmed Paul Trillo.
The ten best short films will be presented at a special premiere event organised by Reply, together with Mastercard, which has always been close to the world of cinema, connecting fans, performers and advocates to their passion. The event will take place during the days of the 81st Venice International Film Festival where the three overall winners will be announced.
To learn more about the Reply AI Film Festival, visit aiff.reply.com.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618976841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
